Friday, August 19, 2022 The CCTG BRC5 abstract was presented at the 2022 World Conference on Lung Cancer in Vienna, Austria as a Plenary 3: Presidential Symposium - Top Rated Abstracts. The presentation concluded that Sublobar resection (including wedge) are equivalent to lobectomy for stage I lung cancer <2cm. There is the potential that this could become a new standard of care with no difference in DFS or OS and similar rates of recurrence. Dr. Nasser Altorki is a Professor of Cardiothoracic Surgery and the Director of the Division of Thoracic Surgery at New York Presbyterian-Weill Cornell Medical Center. Following medical school in Cairo, Egypt, Dr. Altorki completed his residency in general surgery at the University of Chicago Hospital, where he subsequently completed a fellowship in Thoracic and Cardiovascular Surgery. Lobar or Sub-lobar Resection for Peripheral Clinical Stage IA = 2 cm Non-small Cell Lung Cancer (NSCLC): Results From an International Randomized Phase III Trial (CALGB 140503 [Alliance]) Presenter: Nasser Khaled Altorki | Author(s): Xiaofei Wang, David Kozono, Colleeen Watt, Rodney Landreneau, Dennis Wigle, Jeffrey Port, David R Jones, Massimo Conti, Ahmad S Ashrafi, Robert Keenan, Thomas Bauer, Leslie J Kohman, Thomas E Stinchcombe, Everett Vokes https://library.iaslc.org/conference-program?product_id=25&author=conti&category=&date=&session_type=&session=&presentation=&keyword=&cme=undefined& Results: Basic demographic and clinical characteristics were balanced between the two arms of the trial. Minimally invasive approaches were utilized for 80% of all resections. Thirty- and 90-day mortality were 1.1%and 1.7% after lobar resection and 0.6% and 1.2% after sub-lobar resection. With a median follow-up of 7 years, the non-inferiority significance boundary has not been crossed. For DFS, the primary endpoint of the trial, the stratified hazard ratio (HR) was 0.999 (95%CI,0.784 - 1.272, 90% CI, 0.816 - 1.224). For overall survival the stratified HR was 0.930 (95% CI, 0.695 - 1.243, 90% CI, 0.728 - 1.187). In the sub-lobar arm and the lobectomy arm the 5-year DFS rate was 63.9% (95% CI, 58.7-69.5), and 64.3% (95% CI,59.2-69.8), respectively. Conclusions: The results of this large North American/international randomized trial show that for patients with peripheral NSCLC 2 cm or less in size who have pathologically confirmed node-negative disease in major hilar and mediastinal lymph nodes, sub-lobar resection is non-inferior to lobectomy. About BRC5 The BRC5 study - A Phase III Randomized Trial of Lobectomy Versus Sublobular Resection For Small, (</= to 2cm) Peripheral Non-Small Cell Lung Cancer - is a randomized phase III trial is studying different types of surgery to compare how well they work in treating patients with stage IA non-small cell lung cancer. For more information, please visit the CCTG BRC5 trial page. About IASLC The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association’s membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines and more than 100 countries.
